The DOI matches its Crossref record; 158 of the 158 references it cites were found in a registry or an index.
Cell sources for in vitro human liver cell culture models
Open accessAbstract
In vitro liver cell culture models are gaining increasing importance in pharmacological and toxicological research. The source of cells used is critical for the relevance and the predictive value of such models. Primary human hepatocytes (PHH) are currently considered to be the gold standard for hepatic in vitro culture models, since they directly reflect the specific metabolism and functionality of the human liver; however, the scarcity and difficult logistics of PHH have driven researchers to explore alternative cell sources, including liver cell lines and pluripotent stem cells. Liver cell lines generated from hepatomas or by genetic manipulation are widely used due to their good availability, but they are generally altered in certain metabolic functions. For the past few years, adult and pluripotent stem cells have been attracting increasing attention, due their ability to proliferate and to differentiate into hepatocyte-like cells in vitro. However, controlling the differentiation of these cells is still a challenge. This review gives an overview of the major human cell sources under investigation for in vitro liver cell culture models, including primary human liver cells, liver cell lines, and stem cells. The promises and challenges of different cell types are discussed with a focus on the complex 2D and 3D culture approaches under investigation for improving liver cell functionality in vitro. Finally, the specific application options of individual cell sources in pharmacological research or disease modeling are described.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most commonly applied ECM components for hepatocyte cultures are collagen type I and Matrigel, a commercially available BM matrix extract from Engelbreth-Holm-Swarm (EHS) mouse sarcoma (Serna-Márquez et al., 2020[35]; Zeilinger et al., 2016[49]).”
From Optimization of extracellular matrix for primary human hepatocyte cultures using mixed collagen-matrigel matrices (2023) · cites this paper as Zeilinger et al., 2016[49]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Embryonic Stem Cell Lines Derived from Human Blastocysts
Thomson, J. A., Itskovitz‐Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., Marshall, V. S., & Jones, J. M. (1998) · Science · doi:10.1126/science.282.5391.1145 · Cited by 15,947
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
Vascularized and functional human liver from an iPSC-derived organ bud transplant
Takebe, T., Sekine, K., Enomura, M., Koike, H., Kimura, M., Ogaeri, T., Zhang, R.-R., Ueno, Y., Zheng, Y.-W., Koike, N., et al. (2013) · Nature · doi:10.1038/nature12271 · Cited by 2,170
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Self-citationSchwartz, R. E., Reyes, M., Koodie, L., Jiang, Y., Blackstad, M., Lund, T. C., Lenvik, T. R., Johnson, S., Hu, W., & Verfaillie, C. M. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15182 · Cited by 1,030
Bhatia, S. N., Balis, U. J., Yarmush, M. L., & Toner, M. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.14.1883 · Cited by 890
Schwartz, R. E., Reyes, M., Koodie, L., Jiang, Y., Blackstad, M., Lund, T. C., Lenvik, T. R., Johnson, S., Hu, W., & Verfaillie, C. M. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215182 · Cited by 863
Bell, C. C., Hendriks, D. F. G., Moro, S. M. L., Ellis, E., Walsh, J., Renblom, A., Fredriksson Puigvert, L., Dankers, A. C. A., Jacobs, F., Snoeys, J., et al. (2016) · Scientific Reports · doi:10.1038/srep25187 · Cited by 739
Guillouzo, A., Corlu, A., Aninat, C., Glaise, D., Morel, F., & Guguen‐Guillouzo, C. (2006) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.12.003 · Cited by 714
Research works printed but not linked: 5
- Bogoslovsky T, 2013, J Blood Disord Transfus, 4, 158
- Skardal A, 2016, J Vis Exp, 110, e53606
- Wu R, 2006, Int J Mol Med, 18, 339
- Ramboer E, 2015, EXCLI J, 14, 875
- Javed MS, 2014, J Coll Physicians Surg Pak, 24, 91
Cited by
Sorted by citations
Modeling Steatohepatitis in Humans with Pluripotent Stem Cell-Derived Organoids
Ouchi, R., Togo, S., Kimura, M., Shinozawa, T., Koido, M., Koike, H., Thompson, W., Karns, R. A., Mayhew, C. N., McGrath, P. S., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.05.007 · Cited by 537
Scaffold-based 3D cell culture models in cancer research
Abuwatfa, W. H., Pitt, W. G., & Husseini, G. A. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-00994-y · Cited by 372
3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration
Wang, H., Brown, P. C., Chow, E. C. Y., Ewart, L. C., Ferguson, S., Fitzpatrick, S., Freedman, B., Guo, G. L., Hedrich, W. D., Heyward, S. A., et al. (2021) · Clinical and Translational Science · doi:10.1111/cts.13066 · Cited by 232
Interferon and Hepatitis B: Current and Future Perspectives
Ye, J., & Chen, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.733364 · Cited by 177
Engineering 3D Hydrogels for Personalized In Vitro Human Tissue Models
Liaw, C., Ji, S., & Güvendiren, M. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701165 · Cited by 171
A critical perspective on 3D liver models for drug metabolism and toxicology studies
Serras, A. S., Rodrigues, J. S., Cipriano, M., Rodrigues, A. V., Oliveira, N. G., & Miranda, J. P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.626805 · Cited by 138
Models of Drug Induced Liver Injury (DILI)—Current Issues and Future Perspectives
Kuna, L., Bozic, I., Kizivat, T., Bojanic, K., Mrso, M., Kralj, E., Smolic, R., Wu, G. Y., & Smolic, M. (2018) · Current Drug Metabolism · doi:10.2174/1389200219666180523095355 · Cited by 127
In Vitro Models for Non-Alcoholic Fatty Liver Disease: Emerging Platforms and Their Applications
Ramos, M. J., Bandiera, L., Menolascina, F., & Fallowfield, J. A. (2022) · iScience · doi:10.1016/j.isci.2021.103549 · Cited by 127
Herrera‐Balandrano, D. D., Chai, Z., Hutabarat, R. P., Trust Beta, Feng, J., Ma, K., Li, D., & Huang, W. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102100 · Cited by 137
In Vitro and In Vivo Models of Non-Alcoholic Fatty Liver Disease: A Critical Appraisal
Soret, P.-A., Magusto, J., Housset, C., & Gautheron, J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm10010036 · Cited by 121
Human in vitro models of nonalcoholic fatty liver disease
Müller, F. A., & Sturla, S. J. (2019) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2019.03.001 · Cited by 118
Liver Microphysiological Systems for Predicting and Evaluating Drug Effects
Ribeiro, A. J. S., Yang, X., Patel, V. P., Madabushi, R., & Strauss, D. G. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1458 · Cited by 114
Liver organoid as a 3D in vitro model for drug validation and toxicity assessment
Brooks, A., Liang, X., Zhang, Y., Zhao, C., Roberts, M. S., Wang, H., Zhang, L., & Crawford, D. H. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105608 · Cited by 111
Liver organ-on-chip models for toxicity studies and risk assessment
Messelmani, T., Morisseau, L., Sakai, Y., Legallais, C., Goff, A. L., Leclerc, É., & Jellali, R. (2022) · Lab on a Chip · doi:10.1039/d2lc00307d · Cited by 113
Stem-cell based organ-on-a-chip models for diabetes research
Rogal, J., Zbinden, A., Schenke‐Layland, K., & Loskill, P. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.010 · Cited by 89
Mesenchymal Stem Cells for the Treatment of Liver Disease: Present and Perspectives
Kang, S. H., Kim, M. Y., Eom, Y. W., & Baik, S. K. (2020) · Gut and Liver · doi:10.5009/gnl18412 · Cited by 78
Reardon, A. J. F., Farmahin, R., Williams, A., Meier, M. J., Addicks, G. C., Yauk, C. L., Matteo, G., Atlas, E., Harrill, J., Everett, L. J., et al. (2023) · Frontiers in Toxicology · doi:10.3389/ftox.2023.1194895 · Cited by 73
Liver cell therapy: is this the end of the beginning?
Alwahsh, S. M., Rashidi, H., & Hay, D. C. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2713-8 · Cited by 71
Microfluidic Organ-on-a-Chip Devices for Liver Disease Modeling In Vitro
Kanabekova, P., Kadyrova, A., & Kulsharova, G. (2022) · Micromachines · doi:10.3390/mi13030428 · Cited by 73
Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction
Segovia-Zafra, A., Di Zeo-Sánchez, D. E., López-Gómez, C., Pérez-Valdés, Z., García-Fuentes, E., Andrade, R. J., Lucena, M. I., & Villanueva-Paz, M. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.013 · Cited by 70
Nikolic, M. M., Geroski, T., & Filipović, N. (2018) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2018.00120 · Cited by 63
Tutty, M. A., Movia, D., & Prina‐Mello, A. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01147-0 · Cited by 67
Parafati, M., Kirby, R. J., Khorasanizadeh, S., Rastinejad, F., & Malany, S. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.033530 · Cited by 64
Mechanisms and in vitro models of drug-induced cholestasis
Gijbels, E., Vilas‐Boas, V., Deferm, N., Devisscher, L., Jaeschke, H., Annaert, P., & Vinken, M. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02437-2 · Cited by 59
Liver–heart on chip models for drug safety
Ferrari, E., & Rasponi, M. (2021) · APL Bioengineering · doi:10.1063/5.0048986 · Cited by 53
Romualdo, G. R., Leroy, K., Costa, C. J. S., Bacil, G. P., Vanderborght, B., da Silva, T. C., Barbisan, L. F., Andraus, W., Devisscher, L., Câmara, N. O. S., et al. (2021) · Cancers · doi:10.3390/cancers13215583 · Cited by 54
In Vitro Three‐Dimensional Liver Models for Nanomaterial DNA Damage Assessment
Llewellyn, S. V., Niemeijer, M., Nymark, P., Moné, M. J., van de Water, B., Conway, G. E., Jenkins, G. J. S., & Doak, S. H. (2021) · Small · doi:10.1002/smll.202006055 · Cited by 41
Engineering Organ-on-a-Chip to Accelerate Translational Research
Ko, J., Park, D., Lee, S., Gümüşcü, B., & Jeon, N. L. (2022) · Micromachines · doi:10.3390/mi13081200 · Cited by 55
Buick, J. K., Williams, A., Meier, M. J., Swartz, C. D., Recio, L., Gagné, R., Ferguson, S., Engelward, B. P., & Yauk, C. L. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.694834 · Cited by 47
Khairnar, R., Islam, M. A., Fleishman, J. S., & Kumar, S. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121185 · Cited by 49
Seo, J., Tryndyak, V., Wu, Q., Dreval, K., Pogribny, I. P., Bryant, M., Zhou, T., Robison, T. W., Mei, N., & Guo, X. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02406-9 · Cited by 46
Boeri, L., Izzo, L., Sardelli, L., Tunesi, M., Albani, D., & Giordano, C. (2019) · Bioengineering · doi:10.3390/bioengineering6040091 · Cited by 47
Development of organoid-based drug metabolism model
Park, E., Kim, H. K., Jee, J., Hahn, S., Jeong, S., & Yoo, J. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.114790 · Cited by 44
Critical Considerations for the Design of Multi-Organ Microphysiological Systems (MPS)
Malik, M., Yang, Y., Fathi, P., Mahler, G. J., & Esch, M. B. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.721338 · Cited by 43
From organoids to organs: Bioengineering liver grafts from hepatic stem cells and matrix
Willemse, J., Lieshout, R., van der Laan, L. J. W., & Verstegen, M. M. A. (2017) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2017.03.003 · Cited by 44
Ruoß, M., Häussling, V., Schügner, F., Damink, L. H. H. O., Lee, S. M. L., Ge, L., Ehnert, S., & Nussler, A. K. (2018) · Bioengineering · doi:10.3390/bioengineering5040086 · Cited by 44
Smiriglia, A., Lorito, N., Serra, M., Perra, A., Morandi, A., & Kowalik, M. A. (2023) · iScience · doi:10.1016/j.isci.2023.108363 · Cited by 46
Waldherr, M., Mišík, M., Ferk, F., Tomc, J., Žegura, B., Filipič, M., Mikulits, W., Mai, S., Haas, O. A., Huber, W. W., et al. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-2109-4 · Cited by 43
In Vitro Models of the Liver: Disease Modeling, Drug Discovery and Clinical Applications
Collins, S. D., Yuen, G., Tu, T., Budzinska, M. A., Spring, K. J., Bryant, K., & Shackel, N. A. (2019) · Codon Publications eBooks · doi:10.15586/hepatocellularcarcinoma.2019.ch3 · Cited by 42
In vitro functional models for human liver diseases and drug screening: beyond animal testing
Paradiso, A., Volpi, M., Rinoldi, C., Celikkin, N., Contessi Negrini, N., Bilgen, M., Dallera, G., Pierini, F., Costantini, M., Święszkowski, W., et al. (2023) · Biomaterials Science · doi:10.1039/d1bm01872h · Cited by 40
Kim, M. K., Jeong, W., Jeon, S., & Kang, H.-W. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1305023 · Cited by 38
Azparren‐Angulo, M., Royo, F., González, E., Patricio-Liébana, M., Brotons, B., Berganza, J., Goñi‐de‐Cerio, F., Manicardi, N., Abad‐Jordà, L., Gracia‐Sancho, J., et al. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107683 · Cited by 38
Carlessi, R., Köhn‐Gaone, J., Olynyk, J. K., & Tirnitz‐Parker, J. E. E. (2019) · Codon Publications eBooks · doi:10.15586/hepatocellularcarcinoma.2019 · Cited by 39
The Material World of 3D‐Bioprinted and Microfluidic‐Chip Models of Human Liver Fibrosis
Carvalho, A. M., Bansal, R., Barrias, C. C., & Sarmento, B. F. C. C. (2023) · Advanced Materials · doi:10.1002/adma.202307673 · Cited by 36
Bovard, D., Iskandar, A. R., Luettich, K., Hoeng, J., & Peitsch, M. C. (2017) · Toxicology Research and Application · doi:10.1177/2397847317726351 · Cited by 39
IL6 supports long-term expansion of hepatocytes in vitro
Guo, R., Jiang, M., Wang, G., Li, B., Jia, X., Ai, Y., Chen, S., Tang, P., Liu, A., Yuan, Q., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35167-8 · Cited by 36
Sundriyal, S., Chen, P. B., Lubin, A., Lueg, G. A., Li, F., White, A. J. P., Malmquist, N. A., Vedadi, M., Scherf, A., & Fuchter, M. J. (2017) · MedChemComm · doi:10.1039/c7md00052a · Cited by 34
Basu, A., Dydowiczová, A., Čtveráčková, L., Jaša, L., Trosko, J. E., Bláha, L., & Babica, P. (2018) · Environmental Science & Technology · doi:10.1021/acs.est.8b02291 · Cited by 34
Hepatoprotective activity of medicinal plants: A mini review
Jain, D., Chaudhary, P., Kotnala, A., Hossain, R., Bisht, K., & Hossain, M. N. (2020) · Journal of Medicinal Plants Studies · doi:10.22271/plants.2020.v8.i5c.1212 · Cited by 33
Modeling drug-induced liver injury: current status and future prospects
Zeo-Sánchez, D. E. D., Segovia‐Zafra, A., Matilla‐Cabello, G., Pinazo-Bandera, J. M., Andrade, R. J., Lucena, M. I., & Paz, M. V. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2122810 · Cited by 33
Recent advances in models of immune-mediated drug-induced liver injury
Tasnim, F., Huang, X., Lee, C. Z. W., Ginhoux, F., & Yu, H. (2021) · Frontiers in Toxicology · doi:10.3389/ftox.2021.605392 · Cited by 32
Al‐Dhamin, Z., Liu, L., Li, D., Zhang, S., Dong, S., & Nan, Y. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i47.7444 · Cited by 30
Mechanisms of Chronic Fialuridine Hepatotoxicity as Revealed in Primary Human Hepatocyte Spheroids
Hendriks, D. F. G., Hurrell, T., Riede, J., van der Horst, M., Tuovinen, S., & Ingelman-Sundberg, M. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfz195 · Cited by 29
Mouse Models of Hepatocellular Carcinoma: Classification, Advancement, and Application
Liu, S., Huang, F., Ru, G., Wang, Y., Zhang, B., Chen, X., & Chu, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.902820 · Cited by 29
Kapoor, S., Chandel, R., Kaur, R., Kumar, S., Kumar, R., Janghu, S., Kaur, A., & Kumar, V. (2023) · Biochemical Systematics and Ecology · doi:10.1016/j.bse.2023.104702 · Cited by 29
Jiang, J., Pieterman, C., Ertaylan, G., Peeters, R., & de Kok, T. M. C. M. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02585-5 · Cited by 32
Hydrogel-based preparation of cell aggregates for biomedical applications
Zhang, J., Yun, S., Du, Y., Zannettino, A. C. W., & Zhang, H. (2020) · Applied Materials Today · doi:10.1016/j.apmt.2020.100747 · Cited by 30
Chen, L., Yang, Y., Ueno, H., & Esch, M. B. (2020) · Microphysiological Systems · doi:10.21037/mps-19-8 · Cited by 27
Xie, Y., Yao, J., Jin, W., Ren, L., & Li, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.765980 · Cited by 30
Advancements in the Alcohol-Associated Liver Disease Model
Zhu, L., Li, H.-D., Xu, J., Li, J., Cheng, M., Meng, X., Huang, C., & Li, J. (2022) · Biomolecules · doi:10.3390/biom12081035 · Cited by 30
Østbye, T.-K. K., Berge, G. M., Nilsson, A., Romarheim, O. H., Bou, M., & Ruyter, B. (2019) · British Journal Of Nutrition · doi:10.1017/s0007114519001478 · Cited by 27
Direct reprogramming of somatic cells into induced hepatocytes: Cracking the Enigma code
Rombaut, M., Boeckmans, J., Rodrigues, R. M., van Grunsven, L. A., Vanhaecke, T., & Kock, J. D. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.04.048 · Cited by 26
Lahrood, F. N., Saheli, M., Farzaneh, Z., Taheri, P., Dorraj, M., Baharvand, H., Vosough, M., & Piryaei, A. (2019) · Stem Cells and Development · doi:10.1089/scd.2019.0130 · Cited by 25
Youhanna, S. C., Kemas, A. M., Wright, S. C., Zhong, Y., Klumpp, B., Klein, K., Motso, A., Michel, M., Ziegler, N., Shang, M.-M., et al. (2024) · Advanced Science · doi:10.1002/advs.202407572 · Cited by 33
Hollow Fiber and Nanofiber Membranes in Bioartificial Liver and Neuronal Tissue Engineering
Morelli, S., Piscioneri, A., Salerno, S., & Bartolo, L. D. (2021) · Cells Tissues Organs · doi:10.1159/000511680 · Cited by 25
Application of microfluidic chips in the simulation of the urinary system microenvironment
Hou, C., Gu, Y., Yuan, W., Zhang, W., Xiu, X., Lin, J., Gao, Y., Liu, P., Chen, X., & Song, L. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100553 · Cited by 26
Fedi, A., Vitale, C., Fato, M., & Scaglione, S. (2023) · Bioengineering · doi:10.3390/bioengineering10020270 · Cited by 26
Hu, W., Wang, Y., Han, J., Zhang, W., Chen, J., Li, X., & Wang, L. (2025) · Biomaterials Science · doi:10.1039/d4bm01273a · Cited by 27
The Performance of HepG2 and HepaRG Systems through the Glass of Acetaminophen-Induced Toxicity
Lőrincz, T., Deák, V., Makk‐Merczel, K., Varga, D., Hajdinák, P., & Szarka, A. (2021) · Life · doi:10.3390/life11080856 · Cited by 24
Modelling urea cycle disorders using iPSCs
Duff, C. E., & Baruteau, J. (2022) · npj Regenerative Medicine · doi:10.1038/s41536-022-00252-5 · Cited by 24
Modelling fatty liver disease with mouse liver-derived multicellular spheroids
van Os, E. A., Cools, L., Eysackers, N., Szafranska, K., Smout, A., Verhulst, S., Reynaert, H., McCourt, P., Mannaerts, I., & van Grunsven, L. A. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121817 · Cited by 25
Seo, J., Wu, Q., Bryant, M., Ren, L., Shi, Q., Robison, T. W., Mei, N., Manjanatha, M. G., & Guo, X. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02736-z · Cited by 25
Ishida, Y., Yamasaki, C., Iwanari, H., Yamashita, H., Ogawa, Y., Yanagi, A., Furukawa, S., Kojima, Y., Chayama, K., Kamiie, J., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239540 · Cited by 23
Can Transcriptomic Profiles from Cancer Cell Lines Be Used for Toxicity Assessment?
Liu, Z., Zhu, L., Thakkar, S., Roberts, R. A., & Tong, W. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00288 · Cited by 22
Novel organoid model in drug screening: Past, present, and future
Nie, X., Liang, Z., Li, K., Yu, H., Huang, Y., Ye, L., & Yang, Y. (2021) · Liver Research · doi:10.1016/j.livres.2021.05.003 · Cited by 22
In vitro cell-based models of drug-induced hepatotoxicity screening: progress and limitation
Mirahmad, M., Sabourian, R., Mahdavi, M. R., Larijani, B. A., & Safavi, M. (2022) · Drug Metabolism Reviews · doi:10.1080/03602532.2022.2064487 · Cited by 21
Wupperfeld, D., Fricker, G., Fer, B. B. D., Frank, L., Wehrle, A., & Popovic, B. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01698-8 · Cited by 21
Cao, D., Ge, J.-Y., Wang, Y., Oda, T., & Zheng, Y. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i29.4784 · Cited by 19
Hepatic organoids as a platform for liver disease modeling and the development of novel therapies
Luce, E., Messina, A., & Duclos‐Vallée, J. (2025) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2025.102647 · Cited by 23
Lim, A. Y., Kato, Y., Sakolish, C., Valdiviezo, A., Han, G., Bajaj, P., Stanko, J. P., Ferguson, S., Villenave, R., Hewitt, P. G., et al. (2023) · Bioengineering · doi:10.3390/bioengineering10101195 · Cited by 19
Microengineered systems with iPSC-derived cardiac and hepatic cells to evaluate drug adverse effects
Dame, K., & Ribeiro, A. J. S. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370220959598 · Cited by 19
HepaRG Maturation in Silk Fibroin Scaffolds: Toward Developing a 3D In Vitro Liver Model
Abbott, A., & Coburn, J. M. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c01584 · Cited by 19
Sphabmixay, P., Raredon, M. S. B., Wang, A. J.-S., Lee, H., Hammond, P. T., Fang, N. X., & Griffith, L. G. (2021) · Biofabrication · doi:10.1088/1758-5090/ac23aa · Cited by 20
Wang, H., Fan, X., Xie, P., Yang, S. C., Pigeon, P., Xiong, Y., Gai, S., Qi, X., Wang, J., Zhang, Q., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01709 · Cited by 18
Human iPSC-derived liver co-culture spheroids to model liver fibrosis
Cools, L., Dastjerd, M. K., Smout, A., Merens, V., Yang, Y., Reynaert, H., Messaoudi, N., Smet, V. D., Kumar, M., Verhulst, S., et al. (2024) · Biofabrication · doi:10.1088/1758-5090/ad5766 · Cited by 19
Brito, E., Gomes, E. T., Fale, P. L. V., Borges, C., Pacheco, R., Teixeira, V. H., Machuqueiro, M., Ascensão, L., & Serralheiro, M. L. (2018) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2018.04.006 · Cited by 18
Frandsen, H. S., Vej-Nielsen, J. M., Smith, L. E., Sun, L., Mikkelsen, K. L., Thulesen, A. P., Hagensen, C. E., Yang, F., & Rogowska-Wrzesińska, A. (2022) · Cells · doi:10.3390/cells11203216 · Cited by 16
Bi, G., Zhang, X., Li, W., Lu, X., He, X., Li, Y., Bai, R., & Zhang, H. (2024) · Cell Reports Methods · doi:10.1016/j.crmeth.2024.100778 · Cited by 17
Moss, S. M., Schilp, J., Yaakov, M., Cook, M., Schuschke, E., Hanke, B., Strobel, H. A., & Hoying, J. B. (2022) · SLAS DISCOVERY · doi:10.1016/j.slasd.2022.06.003 · Cited by 16
Tamargo-Rubio, I., Simpson, A. B., Hoogerland, J. A., & Fu, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1223108 · Cited by 18
Human Pluripotent Stem-Cell-Derived Models as a Missing Link in Drug Discovery and Development
Lin, X., Tang, J., & Lou, Y. (2021) · Pharmaceuticals · doi:10.3390/ph14060525 · Cited by 16
Analyzing the metabolic fate of oral administration drugs: A review and state-of-the-art roadmap
Liu, L., Liu, Y., Zhou, X., Xu, Z., Zhang, Y., Ji, L., Hong, C., & Li, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.962718 · Cited by 16
Weaver, J. R., Odanga, J. J., Wolf, K., Piekos, S. C., Biven, M., Taub, M. E., LaRocca, J. L., Thomas, C. T., Byer-Alcorace, A., Chen, J., et al. (2022) · Toxicology in Vitro · doi:10.1016/j.tiv.2022.105504 · Cited by 16
Microscale tissue engineering of liver lobule models: advancements and applications
Wang, Q., Liu, J., Yin, W., Wang, A., Zheng, J., Wang, Y., & Dong, J. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1303053 · Cited by 17
Ex Vivo Tools and Models in MASLD Research
Velliou, R.-I., Giannousi, E., Ralliou, C., Kassi, E., & Chatzigeorgiou, A. (2024) · Cells · doi:10.3390/cells13221827 · Cited by 15
Zschiesche, A., Chundela, Z., Thieme, D., & Keiler, A. M. (2021) · Drug Testing and Analysis · doi:10.1002/dta.3184 · Cited by 14
Gao, Y., Gadd, V. L., Heim, M., Grant, R., Bate, T. S. R., Esser, H., Ferreira-González, S., Man, T. Y., Forbes, S. J., & Callanan, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-73827-5 · Cited by 17
Jellali, R., Lereau, M., Tauran, Y., Gilard, F., Danoy, M., Kido, T., Miyajima, A., Sakai, Y., & Leclerc, É. (2019) · Differentiation · doi:10.1016/j.diff.2019.10.006 · Cited by 14
Lee, M., Lee, S., Jung, C., Son, Y. S., Ryu, J.-W., Jung, K. B., Ahn, J., Oh, J., Lee, H., Lim, J. H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24746-w · Cited by 14
Liu, Q., Cai, J., Nichols, R. G., Tian, Y., Zhang, J., Smith, P. B. W., Wang, Y., Yan, C., & Patterson, A. D. (2019) · Metabolites · doi:10.3390/metabo9060118 · Cited by 15
Metadata
- Authors
- Zeilinger, K., Freyer, N., Damm, G., Seehofer, D., & Knöspel, F.
- Affiliations
- Berlin-Brandenburger Centrum für Regenerative Therapien (DE)
- Stiftung Charité (DE)
- Corresponding author
- Zeilinger, Katrin
- Venue
- Experimental Biology and Medicine
- Publisher
- Frontiers Media SA
- Published
- 2016-07-24
- Volume
- 241
- Issue
- 15
- Pages
- 1684-1698
- ISSN
- 0071-3384 (ISSN-L)
- 1535-3702
- 1535-3699
- PMC
- PMC4999620
- OpenAlex
- W2473248288
- Cited by
- 230
- References
- 158
- Citations by year
- 2026: 15 · 2025: 23 · 2024: 24 · 2023: 29 · 2022: 36 · 2021: 39 · 2020: 25 · 2019: 20 · 2018: 14 · 2017: 5
- FWCI
- 16.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Experimental Biology and Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bundesministerium für Bildung und Forschung (0315741)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Keywords
- primary human hepatocytes, liver cell lines, pluripotent stem cells, hepatocyte-like cells, monolayer culture, hepatocyte differentiation, disease modeling, drug metabolism, toxicology
- MeSH terms
- Cell Line, Cells, Cultured, Humans, Liver, Stem Cells, Cell Culture Techniques, Hepatocytes, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
